-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2025-04-20
1AE:F:F-Argen-X (EUR)
COMMON STOCK | Biotechnology |
Last Closing
USD 521.2Change
0.00 (0.00)%Market Cap
USD 34.03BVolume
5.00Analyst Target
N/AVerdict
Verdict
Values as of: 2025-04-20
COMMON STOCK | Biotechnology |
Last Closing
USD 521.2Change
0.00 (0.00)%Market Cap
USD 34.03BVolume
5.00Analyst Target
N/AVerdict
Verdict
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Company Website : https://argenx.com
Currency: EUR
Country : Germany
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
CSJ:F | CSL Limited |
N/A |
USD 70.22B |
CSJA:F | CSL LTD SPON.ADR 2 |
N/A |
USD 70.21B |
RGO:F | Regeneron Pharmaceuticals Inc |
N/A |
USD 67.27B |
UNC0:F | UCB S.A. UNSP.ADR 1/2 |
N/A |
USD 34.17B |
1AEA:F | argenx SE |
N/A |
USD 33.97B |
DUL:F | Alnylam Pharmaceuticals Inc |
N/A |
USD 29.34B |
49BA:F | BeiGene Ltd |
N/A |
USD 27.93B |
49B:F | BeiGene Ltd. |
N/A |
USD 27.93B |
22UA:F | BioNTech SE |
N/A |
USD 21.31B |
RPD:F | ROYALTY PHARMA OA DL-0001 |
N/A |
USD 17.59B |
N/A
Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | -13.25% | 62% | D | 42% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -13.25% | 62% | D | 41% | F | ||
Trailing 12 Months | |||||||
Capital Gain | 56.24% | 86% | B+ | 92% | A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 56.24% | 85% | B | 85% | B | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 20.34% | 77% | C+ | 82% | B | ||
Dividend Return | 20.34% | 77% | C+ | 74% | C | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 21.97% | 86% | B+ | 63% | D | ||
Risk Adjusted Return | 92.59% | 99% | N/A | 90% | A- | ||
Market Capitalization | 34.03B | 99% | N/A | 94% | A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company had negative total cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.